Skip to Main Content

A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation

Conditions

Larynx | Lip, Oral Cavity and Pharynx | Ill-Defined Sites

Phase II

What is the purpose of this trial?

This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy). Patients must be diagnosed with residual disease within 24 weeks of completion of radiation therapy. Residual disease must be biopsy proven before the patient can consent to the trial, and can be either from lymph nodes in the neck, or from the primary tumor site. Prior to beginning study therapy patients are evaluated by an ENT to determine if they have disease amenable to surgical resection. Both resectable and unresectable patients will be eligible for participation in the study.

  • Trial with
    Yale Cancer Center
  • Start Date
    09/07/2016
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Tara McPartland

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/05/2018
  • Study HIC
    #1602017275